View Older Stories View More Recent Stories

Jul 12, 2024 08:30AM AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
Jul 10, 2024 08:00AM AbbVie (ABBV) Appoints Roopal Thakkar as and Chief Scientific Officer
Jul 10, 2024 08:00AM AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
Jul 2, 2024 08:00AM AbbVie to Host Second-Quarter 2024 Earnings Conference Call
Jul 1, 2024 08:00AM AbbVie (ABBV) Appoints Robert A. Michael as CEO
Jul 1, 2024 08:00AM Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
Jun 28, 2024 02:00AM AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Jun 27, 2024 09:27AM AbbVie (ABBV) Acquires Celsius Therapeutics for $250 Million
Jun 27, 2024 09:26AM AbbVie Acquires Celsius Therapeutics
Jun 27, 2024 08:33AM AbbVie (ABBV) Introduces Alle Payment Plans
Jun 27, 2024 08:30AM Introducing Allē Payment Plans, Powered by Cherry
Jun 27, 2024 05:44AM AbbVie (ABBV) Announces Second FDA Approval for EPKINLY
Jun 26, 2024 07:03PM U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
Jun 25, 2024 08:15AM AbbVie (ABBV) Issues US Regulatory Update on ABBV-951
Jun 25, 2024 08:15AM AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
Jun 21, 2024 08:00AM AbbVie Declares Quarterly Dividend
Jun 20, 2024 08:14AM AbbVie (ABBV) Appoints Roxanne S. Austin to its Board
Jun 20, 2024 08:00AM AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
Jun 18, 2024 06:18PM U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
Jun 13, 2024 07:59AM AbbVie (ABBV) and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
Jun 13, 2024 07:59AM AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
Jun 11, 2024 08:00AM BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
Jun 6, 2024 08:45AM AbbVie (ABBV) Announces Positive Topline Results from Phase 2 PICCOLO Trial of Mirvetuximab Soravtansine
Jun 6, 2024 08:45AM AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
Jun 6, 2024 08:30AM SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
Jun 6, 2024 08:00AM AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
Jun 5, 2024 09:00AM AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
Jun 4, 2024 08:30AM RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
Jun 4, 2024 08:05AM Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
Jun 3, 2024 08:30AM AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
May 31, 2024 05:56AM AbbVie (ABBV) Receives Positive CHMP Opinion for Risankizumab
May 31, 2024 02:00AM AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
May 28, 2024 08:00AM AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
May 24, 2024 08:45AM Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 23, 2024 04:05PM AbbVie (ABBV) Completes Acquisition of Landos
May 23, 2024 04:05PM AbbVie Completes Acquisition of Landos Biopharma
May 17, 2024 07:30AM AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
May 13, 2024 08:44AM AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
May 13, 2024 08:39AM AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
May 6, 2024 08:00AM AbbVie to Present at the Bank of America Securities Healthcare Conference
Apr 26, 2024 07:35AM AbbVie Reports First-Quarter 2024 Financial Results
Apr 25, 2024 08:29AM AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
Apr 25, 2024 08:00AM New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Apr 23, 2024 08:00AM Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Apr 18, 2024 08:31AM AbbVie (ABBV) Reports Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis
Apr 18, 2024 08:31AM Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Apr 12, 2024 07:31AM AbbVie (ABBV) Announces Data Supporting Long-Term Safety and Efficacy of Atogepant for Migraine
Apr 12, 2024 07:30AM AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Apr 9, 2024 08:00AM SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
Apr 4, 2024 08:00AM AbbVie to Host First-Quarter 2024 Earnings Conference Call
View More Recent Stories View Older Stories